Is it proper to inquire what the 'Unique characteristics' are?
===============
Thursday January 17, 1:33 pm Eastern Time
Press Release
SOURCE: VIVUS, Inc.
VIVUS Announces FDA Permits Conduct of Clinical Trial With TA-1790 for the Oral Treatment of Erectile Dysfunction
MOUNTAIN VIEW, Calif.--(BW HealthWire)--Jan. 17, 2002--VIVUS, Inc. (Nasdaq:VVUS - news) today announced that as a result of filing a successful Investigational New Drug Application (IND) in December of 2001 the U.S. Food and Drug Administration will permit the Company to initiate a clinical study designed to evaluate the safety and efficacy of TA-1790 for the treatment of erectile dysfunction (ED). TA-1790, licensed from Tanabe Seiyaku in 2001, is a fast acting, highly selective, potent, oral phosphodiesterase type 5 (PDE5) inhibitor. The study will be a multi-center, double-blind, placebo-controlled evaluation of TA-1790 using RigiScan(TM) assessments of erectile response.
``This is a significant first step in the clinical development of TA-1790,'' stated Dr. John Dietrich, Vice President of Research and Development at VIVUS. ``The trial that we will conduct is designed to assess the acute safety and efficacy of orally administered TA-1790 in subjects with erectile dysfunction.''
PDE5 inhibitors, such as Pfizer Inc.'s (NYSE:PFE - news) Viagra®, have been shown to be effective oral treatments for ED. Preclinical studies suggest that TA-1790 has unique characteristics that could allow it to compete in the ED marketplace.
<abridged>
biz.yahoo.com
===============
(VVUS was up 15+% today (on huge volume) and is up 60+% YTD)
BTW, the other company I mentioned on this thread which announced plans for advanced clinical trials (Delcath Systems, DCTH) was up about 25% today and is up about 70% YTD. |
